Status:
COMPLETED
EMR Data to Assess Monitoring of Patients Treated With Quetiapine
Lead Sponsor:
AstraZeneca
Conditions:
Schizophrenia
Bipolar Disorder
Eligibility:
All Genders
18+ years
Brief Summary
A study to evaluate the effectiveness of an update of educational materials with respect to evaluation of monitoring of metabolic parameters
Detailed Description
Objective assessment of metabolic monitoring in patients treated with Seroquel® or Seroquel® XR/quetiapine fumarate: use of IMS Disease Analyzer to assess physician behaviour in the UK and Germany
Eligibility Criteria
Inclusion
- \- Electronic medical records of patients with diagnoses of schizophrenia, Bipolar Disorder (BPD) or Major Depressive Disorder (MDD) treated with Seroquel® or Seroquel®XR during the calendar periods: 13 Feb - 31 Aug 2012 seen by GP \& psychiatrists in Germany \& 11 Jan-31 July 2012 seen by GPs in the UK
Exclusion
- \- Patients with above mentioned diagnoses treated with Seroquel® or Seroquel® XR/quetiapine fumarate not having any medical encounters during the time periods: 13 Feb - 31 Aug 2012 in Germany \& 11 Jan-31 July 2012 by GPs in the UK
Key Trial Info
Start Date :
April 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2013
Estimated Enrollment :
6153 Patients enrolled
Trial Details
Trial ID
NCT01793324
Start Date
April 1 2012
End Date
June 1 2013
Last Update
January 28 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.